



**ACKNOWLEDGMENTS**

The authors have declared that no AI tools were used during the preparation of this work.

**AUTHOR CONTRIBUTIONS**

TMB: Data collection, writing of the manuscript.

IA, MLA, AA, LR, RF: Data collection, critical review of the manuscript.

All authors approved the final version to be published.

**PROTECTION OF HUMANS AND ANIMALS**

The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association updated in October 2024.

**REFERENCES**

1. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2022;97:352-72.
2. Haroche J, Charlotte F, Arnaud L, von Deimling A, Hélias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. *Blood*. 2012;120:2700-3.
3. Papo M, Diamond EL, Cohen-Aubart F, Emile J-F, Roos-Weil D, Gupta N, et al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. *Blood*. 2017;130:1007-13.
4. Bonnet P, Chasset F, Moguelet P, Abisror N, Itzykson R, Bouaziz J-D, et al. Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation. *Haematologica*. 2019;104:e530-3.
5. Goyal G, Liu Y, Ravindran A, Al-Kali A, Go RS, Patnaik MM, et al. Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. *Br J Haematol*. 2019;187:e51-4.

**DATA CONFIDENTIALITY**

The authors declare having followed the protocols in use at their working center regarding patients' data publication.

**PATIENT CONSENT**

Obtained.

**CONFLICTS OF INTEREST**

The authors have no conflicts of interest to declare.

**FUNDING SOURCES**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Tiago MONTEIRO-BRÁS <sup>1</sup>, Inês ARAÚJO<sup>2</sup>, Maria Luísa AMORIM <sup>3</sup>, Alexandra AZEVEDO<sup>4</sup>, Luísa REGADAS<sup>1</sup>, Raquel FARIA <sup>5</sup>, Rita COUTINHO <sup>6,7</sup>

1. Department of Hematology. Centro Hospitalar Universitário de Santo António. Unidade Local de Saúde de Santo António. Porto. Portugal.
2. Anatomic Pathology Service. Centro Hospitalar Universitário de Santo António. Unidade Local de Saúde de Santo António. Porto. Portugal.
3. Department of Hematology. Centro Hospitalar Universitário de São João. Unidade Local de Saúde de São João. Porto. Portugal.
4. Department of Dermatology. Hospital Militar das Forças Armadas (Pólo do Porto). Porto. Portugal.
5. Clinical Immunology Unit. Centro Hospitalar Universitário de Santo António. Unidade Local de Saúde de Santo António. Porto. Portugal.
6. Department of Hematology and Bone Marrow Transplantation. Instituto Português de Oncologia do Porto Francisco Gentil. Porto. Portugal.
7. Instituto de Investigação e Inovação em Saúde (i3S). Universidade do Porto. Porto. Portugal.

✉ **Autor correspondente:** Tiago Monteiro-Brás. [tiagobras@chporto.min-saude.pt](mailto:tiagobras@chporto.min-saude.pt)

**Revisto por/Reviewed by:** Carlos Couto Faria.

**Recebido/Received:** 12/11/2025 - **Aceite/Accepted:** 30/01/2026 - **Publicado/Published:** 02/03/2026

Copyright © Ordem dos Médicos 2026

<https://doi.org/10.20344/amp.24231>

